Quick answer
How is a four-peptide KLOW vial reconstituted for laboratory work? The procedure is the same as for any co-lyophilized peptide: equilibrate the sealed vial, add diluent slowly down the glass wall, swirl until the cake dissolves and aliquot. What is specific to this product is the arithmetic and the bookkeeping. The V8 product page lists the KLOW Stack (GHK-Cu, KPV, BPC-157 and TB-500) as one 80 mg blend with the molecular formula given as "Blend"; the split between the four components is reported on the certificate of analysis where published. Total concentration is the vial mass divided by the diluent volume, and a component's concentration is its documented mass divided by that same volume. This guide sets out those formulas, the choices a four-component solution forces and a record sheet, without per-volume tables, because the reconstitution calculator does the arithmetic for the specific vial. For laboratory research use only.
Questions about reconstituting this stack usually ask for a single number: how much water to add. There is no universal figure, because the right volume depends on the concentration the experiment needs, and for a four-peptide blend, it also depends on which component is the limiting one. This article explains the reasoning so the calculation can be done for any vial, and covers the chemistry that makes a four-component solution different from a single peptide. For compound background see the KLOW stack research overview and KLOW stack explained; for the basic procedure shared by every product, how to reconstitute a lyophilized peptide. Everything here concerns laboratory work; the material is for laboratory research use only and not for human consumption.
What is in the vial
According to the KLOW Stack product page, the vial is a four-peptide research blend supplied as one co-lyophilized cake with 80 mg of total peptide, at a purity specification of ≥98% by HPLC, in a sealed clear glass research vial. Storage is 2–8 °C, with −20 °C for the long term and protection from heat, moisture and light. The four components are quite different molecules.
| Component | Nature | Size | Notable chemistry for handling |
|---|---|---|---|
| GHK-Cu | Copper(II) complex of the tripeptide Gly-His-Lys | 3 residues plus metal | Blue complex; copper binds the histidine imidazole and amine groups; light-sensitive |
| KPV | Lys-Pro-Val, C-terminal tripeptide of α-MSH | 3 residues | Small, soluble, cationic |
| BPC-157 | Synthetic pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | 15 residues | Proline-rich; no cysteine, methionine or tryptophan; Asp-Asp and Asp-Ala motifs |
| TB-500 | Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, fragment of thymosin β4 | 7 residues | Acetylated N-terminus; polar and charged; no aromatic residues |
The product page does not give the mass of each component. That information belongs on the certificate where one has been published; the COA library lists them, and how to read a COA explains the fields. If the split is not documented for the lot in hand, the honest entry in the lab record is "unknown", not an assumed equal split. The ratio is the difference between this vial and a single-peptide vial: the other peptides are in it by design.
The arithmetic, as formulas
Three relationships cover every case. They are deliberately given as formulas, not as a list of volumes, because the answer depends on the vial in hand and the concentration the experiment needs.
- Total concentration = vial mass ÷ diluent volume. For an 80 mg vial the vial mass is 80 mg; the diluent volume is whatever is added.
- Component concentration = documented component mass ÷ diluent volume. The four component concentrations add up to the total.
- Diluent volume for a target = component mass ÷ target concentration of that component. The same volume produces a different concentration for each component, so a target is defined for one component, and the others follow.
The third formula is the one that matters for planning. In a four-component blend, a single diluent volume cannot give equal molar or equal mass concentrations of all components unless the masses happen to be equal. Decide which component the experiment is built around, calculate the volume from that component's mass, and record what the others come to. If concentrations of a minor component are too low at that volume, a second vial of single peptide can be used to supplement it, with its own arm in the design.
Mass is not the same as moles. A tripeptide such as KPV has a far lower molar mass than the 15-residue BPC-157, so equal masses contain many more molecules of the smaller peptide. If the assay is built on molar concentration, convert each component with its molar mass (mass ÷ molar mass = moles). GHK-Cu is counted as the copper complex, and the counterion content of each peptide means the weighed mass may exceed the net peptide mass; the certificate is where net peptide content is reported if it is reported at all. The calculator and its guide handle the volume step, and peptide reconstitution volume calculations shows the reasoning behind it.
Choosing the diluent
| Situation | Diluent | Reasoning |
|---|---|---|
| A vial that will be entered many times over days | Bacteriostatic water | The benzyl alcohol preservative limits microbial growth between entries; include it in the vehicle control |
| A stock divided at once into frozen single-use aliquots | Sterile water | No additive; freezing stops growth; no preservative effects on cells |
| A buffered assay | Water first, then buffer on dilution | Keeps pH and salts from changing the cake's dissolution before the peptides are fully in solution |
| A system sensitive to benzyl alcohol | Sterile water | Preservative may affect some cell types; test the vehicle alone |
The bacteriostatic water explanation covers the preservative in detail; preservative effects on a given cell type should be tested in a vehicle-only arm.
Why four components change the handling
Copper and the other peptides
GHK-Cu holds copper(II) through the histidine imidazole, the amino terminus and backbone amides. Pickart and Margolina (2018) review the biology of the complex. In solution with three other peptides, the question is whether copper moves. KPV and TB-500 have no histidine, and BPC-157 has none either, so none is a strong copper ligand; the metal is expected to remain with GHK. A copper-salt control and single-component arms are the way to confirm that in a particular assay. Does copper degrade other peptides in a blend goes through the argument in more detail.
Adsorption
Cationic peptides, which includes all four here (lysine-rich KPV and TB-500, and BPC-157 with its single lysine and Asp/Glu balance), adsorb to glass and some plastics, as described by Goebel-Stengel and colleagues (2011). An 80 mg stock is concentrated enough that adsorption is a small fraction of the whole, but dilutions made for cell work are where it matters.
Chemical stability
None of the four contains cysteine, methionine or tryptophan, so the oxidation routes reviewed by Li and colleagues (1995) are limited. Histidine can be modified in the presence of metal ions and light. BPC-157's Asp-Asp and Asp-Ala motifs are the places where isomerization could occur over long storage in solution, a known pathway for aspartyl residues. The practical consequence is the same for all: keep solutions cold, dark and short-lived.
Stress from handling
Agitation, freeze–thaw and surfaces cause aggregation and loss in peptide solutions, as summarized by Manning and colleagues (2010) and Hawe and colleagues (2012). With four components, none is exempt, so the same conservative handling applies to all.
Reconstitution step by step
- Remove the vial from storage and let it reach room temperature unopened, to avoid condensation on the cake.
- Wipe the stopper, record the lot and the date, and note the appearance of the cake (blue to blue-green is expected because of the copper complex).
- Calculate the diluent volume with the formulas above or the calculator, for the component and concentration the experiment is built on.
- Add diluent slowly down the inside wall of the vial; do not aim at the cake.
- Swirl gently until clear. Do not vortex or shake; vigorous agitation foams and stresses the longer peptides.
- Check clarity and color. Record both. A hazy or particulate solution is a reason to stop and document.
- Divide into single-use aliquots in low-binding tubes, label each with lot, date, total concentration and component concentrations, and freeze those not used at once.
- Thaw an aliquot once, use it and discard the remainder.
For how long solutions last, see how long reconstituted peptides last and KLOW stack reconstitution and storage; a cloudy result is discussed in cloudy peptide vial after reconstitution.
What published preclinical work used, at the concentration level
A reconstitution plan is only useful if it matches the range an experiment needs. The literature on the four components is, for the most part, expressed per component and per system, not for blends. Examples include in vitro tendon fibroblast work with BPC-157 by Chang and colleagues (2011), keratinocyte migration work with thymosin β4 by Malinda and colleagues (1999), and KPV work in intestinal epithelial and murine models by Dalmasso and colleagues (2008). The parameters in each paper, such as species, route and concentration range, are in the papers themselves. No published study of this exact four-component mixture is cited here, so any concentration for the blend must be derived from the single-component literature and tested; this article does not recommend one.
Record sheet for a four-component stock
- Lot number; certificate status; documented mass of each component, or "unknown".
- Diluent, diluent lot, volume added and the formula result for total and component concentrations.
- Cake and solution appearance at preparation.
- Aliquot number, volume and storage temperature; freeze–thaw count.
- Single-component, copper-salt and vehicle controls run in parallel.
The comparison with the three-component version is in Glow vs KLOW vs Wolverine, background on stacks as a format is in peptide blends and research stacks and purity data are explained in KLOW stack purity testing. Further materials are listed in the shop. The product is supplied for laboratory research use only; nothing in this article is a recommendation for use in people or animals.
Frequently asked questions
What does the KLOW Stack product page list?
A four-peptide blend of GHK-Cu, KPV, BPC-157 and TB-500 as one co-lyophilized 80 mg vial, ≥98% HPLC purity, molecular formula given as Blend, with component details on the certificate where published.
How is the concentration of the whole solution calculated?
Vial mass divided by diluent volume. For an 80 mg vial that is 80 mg divided by the volume added.
How is a single component's concentration found?
Its documented mass divided by the same diluent volume. The component masses come from the certificate of analysis where one is published.
Is there one correct volume of diluent?
No. The volume depends on the target concentration and on which component the experiment is built around. The reconstitution calculator does the arithmetic for a given vial.
Why can one volume not equalize all four components?
The components are present in different masses and have different molar masses, so one volume gives each a different concentration.
Which diluent suits a vial entered many times?
Bacteriostatic water, because the preservative limits growth between entries. Include it in the vehicle control.
Why is the solution blue?
GHK binds copper(II) to form a blue complex. A blue cake and solution are expected.
How should the solution be mixed?
Add diluent slowly along the vial wall and swirl gently. Avoid shaking or vortexing.
How should the sealed vial be stored?
The product page states 2–8 °C, with −20 °C for the long term, protected from heat, moisture and light.
Is the KLOW Stack for use in people or animals?
No. It is supplied for laboratory research use only and is not for human or animal consumption.
Related reading: KLOW Stack: Component Evidence and Interaction Design.
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
